Next Article in Journal
Reference Values on Children’s Hair for 28 Elements (Heavy Metals and Essential Elements) Based on a Pilot Study in a Representative Non-Contaminated Local Area
Next Article in Special Issue
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies
Previous Article in Journal
Benzoquinoline Derivatives: An Attractive Approach to Newly Small Molecules with Anticancer Activity
Previous Article in Special Issue
Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?
 
 
Review
Peer-Review Record

Small-Cell Lung Cancer—An Update on Targeted and Immunotherapies

Int. J. Mol. Sci. 2023, 24(9), 8129; https://doi.org/10.3390/ijms24098129
by Nicholas McNamee 1, Ines Pires da Silva 1,2, Adnan Nagrial 1,2 and Bo Gao 1,2,*
Reviewer 1: Anonymous
Reviewer 2:
Int. J. Mol. Sci. 2023, 24(9), 8129; https://doi.org/10.3390/ijms24098129
Submission received: 2 April 2023 / Revised: 23 April 2023 / Accepted: 29 April 2023 / Published: 1 May 2023

Round 1

Reviewer 1 Report

The current manuscript is an interesting review on old and new therapies for small-cell lung cancer. It is overall quite thorough and complete, nevertheless some alterations should be made before acceptance for publication:

- The review lacks illustrative images, authors should add, for example, an image illustrating current vs new treatments, and related advantages and limitations; and an image regarding the diseases pathophysiology;

- The meaning of some abbreviations is lacking, for example “PDL1”; while this might be basic knowledge for the authors, defining all abbreviations will help researchers from different fields better understand what is being said;

- A “Conclusion” section is missing, apart from the “Discussion” section.

Author Response

Please see attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Please add comments concerning the CAPSTONE-1 and Astrum-005 trials in the Immunotherapy paragraph and ed edit the table. 

Please report data concerning Tarlatamb efficacy in the section concerning the new treatments. 

Author Response

Please see attachment

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

I think it's situable for the pubblication now

Back to TopTop